<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADDERALL- dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfateÂ tabletÂ </strong><br>Teva Select Brands<br></p></div>
<h1>
<span class="Bold">Adderall<span class="Sup">Â®</span> CII</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product))</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_table_id_487b50ec-49c6-472d-930f-7e3b9d663c75"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">PROLONGED PERIODS</span> OF TIME MAY LEAD TO <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">DRUG DEPENDENCE</span> AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.</p>
<p>MISUSE OF AMPHETAMINE MAY CAUSE <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">SUDDEN DEATH</span> AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_624bf74e-f407-4e2c-98e8-c88049855d55"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">A single-entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate.</p>
<table width="100%">
<col width="37%">
<col width="9%">
<col width="10%">
<col width="8%">
<col width="10%">
<col width="9%">
<col width="8%">
<col width="8%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>1.25 mg of Amphetamine Aspartate Monohydrate equivalent to 1.17 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>1.875 mg of Amphetamine Aspartate Monohydrate equivalent to 1.755 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>2.5 mg of Amphetamine Aspartate Monohydrate equivalent to 2.34 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd>3.125 mg of Amphetamine Aspartate Monohydrate equivalent to 2.925 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â¶</a></dt>
<dd>3.75 mg of Amphetamine Aspartate Monohydrate equivalent to 3.51 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>5 mg of Amphetamine Aspartate Monohydrate equivalent to 4.6 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Ãž</a></dt>
<dd>7.5 mg of Amphetamine Aspartate Monohydrate equivalent to 7.03 mg Amphetamine Aspartate (Anhydrous) as supplied</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">EACH TABLET CONTAINS:</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">7.5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">10 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">12.5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">15 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">20 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline">30 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Dextroamphetamine</p>
<p>Saccharate </p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.875 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2.5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.125 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.75 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.5 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Amphetamine Aspartate Monohydrate Equivalent </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.875 mg<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2.5 mg<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.125 mg<a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.75 mg<a name="footnote-reference-5" href="#footnote-5" class="Sup">Â¶</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.5 mg<a name="footnote-reference-7" href="#footnote-7" class="Sup">Ãž</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Dextroamphetamine</p>
<p>Sulfate, USP</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.875 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2.5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.125 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.75 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.5 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Amphetamine</p>
<p>Sulfate, USP</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.875 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2.5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.125 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.75 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.5 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Total Amphetamine Base Equivalence</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.13 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4.7 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6.3 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.8 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">9.4 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">12.6 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">18.8 mg</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_754a087c-ad9f-4d81-880f-b434fe6c422d"></a><a name="section-1.1"></a><p></p>
<h2>Inactive Ingredients: colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, microcrystalline cellulose and saccharin sodium.</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1e7e4fd7-a1e1-48c3-ae33-672f120c1868"></a><a name="section-1.2"></a><p></p>
<h2>Colors:	Adderall<span class="Sup">	Â® </span>	5 mg is a white to off-white tablet, which contains no color additives.</h2>
<dl>
<dt>Â </dt>
<dd>Adderall<span class="Sup"> Â®</span> 7.5 mg and 10 mg contain FD&amp;C Blue #1 Aluminum Lake as a color additive.</dd>
<dt>Â </dt>
<dd>Adderall<span class="Sup"> Â®</span> 12.5 mg, 15 mg, 20 mg and 30 mg contain FD&amp;C Yellow #6 Aluminum Lake as a color additive.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a157b0ee-99be-47fd-890c-12e730183f3b"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9311c14c-ace9-46d3-a186-7a230ef23cca"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>) is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d32223c4-3a0a-4add-a91c-a203a00d03ca"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Adderall<span class="Sup">Â®</span> tablets contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following administration of a single dose 10 or 30 mg of Adderall<span class="Sup">Â®</span> to healthy volunteers under fasted conditions, peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and l-amphetamine. The mean elimination half-life (t<span class="Sub">1/2</span>) for d-amphetamine was shorter than the t<span class="Sub">1/2</span> of the l-isomer (9.77 to 11 hours vs. 11.5 to 13.8 hours). The PK parameters (C<span class="Sub">max</span>, AUC<span class="Sub">0-inf</span>) of d-and l-amphetamine increased approximately three-fold from 10 mg to 30 mg indicating dose-proportional pharmacokinetics.</p>
<p>The effect of food on the bioavailability of Adderall<span class="Sup">Â®</span> has not been studied.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb30776c-f7e4-49e1-9777-349b32dacb47"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Italics">Metabolism and Excretion</span></h3>
<p class="First">Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain Î± or Î² carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.</p>
<p>Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. <span class="Italics">In vitro</span> experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to <span class="Italics">in vivo</span> concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes <span class="Italics">in vivo</span> can be made.</p>
<p>With normal urine pHs approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30% to 40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that affect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamineâ€™s metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased (see<span class="Bold"><a href="#i4i_precautions_id_748a70c6-f7b2-481e-a706-ed9eb93f9528">PRECAUTIONS</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_29a35259-a305-4821-ad39-1a93075c30b4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is indicated for the treatment of Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>) and <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_269a89d5-2dfe-4876-bfce-6c3e5b94bc7e"></a><a name="section-3.1"></a><p></p>
<h2>Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>)</h2>
<p class="First">A diagnosis of Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>; DSM-IV<span class="Sup">Â®</span>) implies the presence of <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorder</span>. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactive</span>-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; â€œon the go;â€? excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive criteria to be met.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c81b1448-1db4-41a2-a31b-df7cc98fc4ae"></a><a name="section-3.2"></a><p></p>
<h2>Special Diagnostic Considerations</h2>
<p class="First">Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV<span class="Sup">Â®</span> characteristics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f34bf164-6209-4b50-a1f3-4f3945a3d8d3"></a><a name="section-3.3"></a><p></p>
<h2>Need for Comprehensive Treatment Program</h2>
<p class="First">Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is indicated as an integral part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb510637-494d-4b43-9f77-23f14c0beec5"></a><a name="section-3.4"></a><p></p>
<h2>Long-Term Use</h2>
<p class="First">The effectiveness of Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_721cff5b-2b72-414a-8a7d-2dafc2b74190"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Advanced <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, symptomatic cardiovascular disease, moderate to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or idiosyncrasy to the sympathomimetic amines, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states.</p>
<p>Patients with a history of drug abuse.</p>
<p>During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_be594b93-1a08-4e9c-a576-d3873f47170c"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de15f5ee-119c-4702-8c3f-e78cb0f1d3a5"></a><a name="section-5.1"></a><p></p>
<h2>Serious Cardiovascular Events</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_067a292b-5b97-4a60-b2de-3d70aa61cfd5"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden Death</span> and Preexisting Structural Cardiac Abnormalities or Other Serious Heart Problems</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5299c57-3f76-4b9d-9fd2-99b8752a14e4"></a><a name="section-5.1.1.1"></a><p></p>
<h4><span class="Underline">Children and Adolescents</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.</p>
<p>Although some structural heart problems alone may carry an increased risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, stimulant products generally should not be used in children or adolescents with known structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug (see <span class="Bold"><a href="#i4i_contraindications_id_721cff5b-2b72-414a-8a7d-2dafc2b74190">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc5e79b2-ac4d-487d-ba1d-637c5c7b5d8c"></a><a name="section-5.1.1.2"></a><p></p>
<h4><span class="Underline">Adults</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden deaths</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported in adults taking stimulant drugs at usual doses for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see <span class="Bold"><a href="#i4i_contraindications_id_721cff5b-2b72-414a-8a7d-2dafc2b74190">CONTRAINDICATIONS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba0e36d3-7589-4339-94f6-dcf553cd1d6c"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and Other Cardiovascular Conditions</span></h3>
<p class="First">Stimulant medications cause a modest increase in average blood pressure (about 2 to 4 mmHg) and average heart rate (about 3 to 6 bpm) [see <span class="Bold"><a href="#i4i_adverse_effects_id_9c08662d-1da7-408f-99fd-8aee26f1f706">ADVERSE REACTIONS</a></span>], and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> (see <span class="Bold"><a href="#i4i_contraindications_id_721cff5b-2b72-414a-8a7d-2dafc2b74190">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a555b3e9-82af-4fe4-a250-df798e4ed436"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="Italics">Assessing Cardiovascular Status in Patients Being Treated With Stimulant Medications</span></h3>
<p class="First">Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78b4b2b0-f866-41b2-bfd2-3fe692609ca5"></a><a name="section-5.2"></a><p></p>
<h2>Psychiatric Adverse Events</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e15fb90a-3594-4b35-923a-4e7e6b230539"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="Italics">Preexisting <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span></h3>
<p class="First">Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with preexisting <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorder</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8993fe2b-c378-4068-a269-3334eb155654"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="Italics">Bipolar Illness</span></h3>
<p class="First">Particular care should be taken in using stimulants to treat <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> patients with comorbid bipolar disorder because of concern for possible induction of mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in such patients. Prior to initiating treatment with a stimulant, patients with comorbid <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4588d50c-e204-44fb-b141-c098e405cc95"></a><a name="section-5.2.3"></a><p></p>
<h3><span class="Italics">Emergence of New <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Symptoms</span></h3>
<p class="First">Treatment emergent <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms, e.g., <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, delusional thinking, or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in children and adolescents without prior history of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f4bd5a4-ffc0-4337-93e0-de3ec7212d0a"></a><a name="section-5.2.4"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> is often observed in children and adolescents with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. Although there is no systematic evidence that stimulants cause <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, patients beginning treatment for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> should be monitored for the appearance of or worsening of <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17211737-5051-4a4c-be37-55fa59133849"></a><a name="section-5.3"></a><p></p>
<h2>Long-Term Suppression of Growth</h2>
<p class="First">Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they will likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00b24916-f876-490f-ad35-37943ce5c559"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, in patients with prior EEG abnormalities in absence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and very rarely, in patients without a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and no prior EEG evidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In the presence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29cbdabf-fa27-462f-b6d4-126e2e7c3a9c"></a><a name="section-5.5"></a><p></p>
<h2>Peripheral Vasculopathy, Including Raynaudâ€™s Phenomenon</h2>
<p class="First">Stimulants, including Adderall<span class="Sup">Â®</span>, used to treat <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> are associated with peripheral vasculopathy, including Raynaudâ€™s phenomenon.  Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown.  Effects of peripheral vasculopathy, including Raynaudâ€™s phenomenon, were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment.  Signs and symptoms generally improve after reduction in dose or discontinuation of drug.  Careful observation for digital changes is necessary during treatment with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> stimulants.  Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90fc0490-1e25-44b9-92e2-b973c544e9c3"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbance</span></h2>
<p class="First">Difficulties with accommodation and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> have been reported with stimulant treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_748a70c6-f7b2-481e-a706-ed9eb93f9528"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_4823fe7f-dead-40cf-aa5b-fd815e771505"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Adderall<span class="Sup">Â®</span> should be used with caution in patients who use other sympathomimetic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0ce3780-40b8-43d6-a224-07f1ceab983b"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">Tics</span></h2>
<p class="First">Amphetamines have been reported to exacerbate motor and phonic <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> and Touretteâ€™s syndrome. Therefore, clinical evaluation for <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> and Touretteâ€™s syndrome in children and their families should precede use of stimulant medications.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_24724957-1c14-4355-a36d-aaef389fbe35"></a><a name="section-6.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.</p>
<p>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with amphetamine or dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for Adderall<span class="Sup">Â®</span>.</p>
<p>The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d24e0ef-1e6b-4142-8b02-5fdf295c6987"></a><a name="section-6.3.1"></a><p></p>
<h3><span class="Italics">Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaudâ€™s Phenomenon]</span></h3>
<dl>
<dt>â€¢</dt>
<dd>Instruct patients beginning treatment with Adderall<span class="Sup">Â® </span>about the risk of peripheral vasculopathy, including Raynaudâ€™s phenomenon, and associated signs and symptoms:  fingers or toes may feel numb, cool, painful, and/or may change color from <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, to blue, to red.</dd>
<dt>â€¢</dt>
<dd>Instruct patients to report to their physician any new <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, skin color change, or sensitivity to temperature in fingers or toes.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Instruct patients to call their physician immediately with any signs of unexplained <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> appearing on fingers or toes while taking Adderall<span class="Sup">Â®</span>.</span></dd>
<dt>â€¢</dt>
<dd>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c3068b7-9144-4d0b-a460-01efd2b64ea2"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_893c2c36-7d37-4a0f-a89a-6266dfac0694"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Italics">Acidifying Agents</span></h3>
<p class="First">Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c6fe139-7793-4fe2-97a5-f144d637ad6d"></a><a name="section-6.4.1.1"></a><p></p>
<h4><span class="Underline">Urinary Acidifying Agents</span></h4>
<p class="First">(ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c41a1e5-7dba-4e3d-a181-d85f0e00ef5d"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="Italics">Adrenergic Blockers</span></h3>
<p class="First">Adrenergic blockers are inhibited by amphetamines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a0f3fec-9999-471c-a7d5-61839f01cc43"></a><a name="section-6.4.3"></a><p></p>
<h3><span class="Italics">Alkalinizing Agents</span></h3>
<p class="First">Gastrointestinal alkalinizing agents (sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, etc.) increase absorption of amphetamines. Coadministration of Adderall<span class="Sup">Â®</span> and gastrointestinal alkalizing agents, such as antacids, should be avoided. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87ef97da-ec72-437c-9fc9-544c70f494ae"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="Italics">Antidepressants, Tricyclic</span></h3>
<p class="First">Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c4a671f-ff7b-4aed-95e7-b55e8dbfb55d"></a><a name="section-6.4.5"></a><p></p>
<h3><span class="Underline">MAO Inhibitors</span></h3>
<p class="First">MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and other signs of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. A variety of neurological toxic effects and <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperpyrexia</span> can occur, sometimes with fatal results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1692e5ce-2344-4447-91ec-face8153eccf"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="Italics">Antihistamines</span></h3>
<p class="First">Amphetamines may counteract the sedative effect of antihistamines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a5696dcd-56e2-4ab5-9258-fe6aa7fe6747"></a><a name="section-6.4.7"></a><p></p>
<h3><span class="Italics">Antihypertensives</span></h3>
<p class="First">Amphetamines may antagonize the hypotensive effects of antihypertensives.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f7d1692-fddf-402f-a2bf-6bcf954a9ee7"></a><a name="section-6.4.8"></a><p></p>
<h3><span class="Italics">Chlorpromazine</span></h3>
<p class="First">Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84927791-009f-4922-9c28-11d71fa76f62"></a><a name="section-6.4.9"></a><p></p>
<h3><span class="Italics">Ethosuximide</span></h3>
<p class="First">Amphetamines may delay intestinal absorption of ethosuximide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7f7469a-aa12-4855-8d76-b169dbc503af"></a><a name="section-6.4.10"></a><p></p>
<h3><span class="Italics">Haloperidol</span></h3>
<p class="First">Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9fe9a46-85da-464f-97d8-9afd3d1926c2"></a><a name="section-6.4.11"></a><p></p>
<h3><span class="Italics">Lithium Carbonate</span></h3>
<p class="First">The <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> and stimulatory effects of amphetamines may be inhibited by lithium carbonate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a7477ee-cf39-4641-8aff-88fcbce33408"></a><a name="section-6.4.12"></a><p></p>
<h3><span class="Italics">Meperidine</span></h3>
<p class="First">Amphetamines potentiate the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of meperidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b861aeb-4bb8-4a93-af07-a48df9be956a"></a><a name="section-6.4.13"></a><p></p>
<h3><span class="Italics">Methenamine Therapy</span></h3>
<p class="First">Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7cb74c5f-9c1b-44e3-a73d-73bf2246cfb6"></a><a name="section-6.4.14"></a><p></p>
<h3><span class="Italics">Norepinephrine</span></h3>
<p class="First">Amphetamines enhance the adrenergic effect of norepinephrine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d089905-f3c6-4d73-8a43-44e5a3b3e5da"></a><a name="section-6.4.15"></a><p></p>
<h3><span class="Italics">Phenobarbital</span></h3>
<p class="First">Amphetamines may delay intestinal absorption of phenobarbital; coadministration of phenobarbital may produce a synergistic anticonvulsant action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5543588-e2cf-4356-b191-0f9a5457d363"></a><a name="section-6.4.16"></a><p></p>
<h3><span class="Italics">Phenytoin</span></h3>
<p class="First">Amphetamines may delay intestinal absorption of phenytoin; coadministration of phenytoin may produce a synergistic anticonvulsant action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb575fee-4cc5-4f82-ae62-466c6bcb1dcb"></a><a name="section-6.4.17"></a><p></p>
<h3><span class="Italics">Propoxyphene</span></h3>
<p class="First">In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> can occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a825c448-19e5-49d6-916b-258ea3371524"></a><a name="section-6.4.18"></a><p></p>
<h3><span class="Italics">Proton Pump Inhibitors</span></h3>
<p class="First">PPIs act on proton pumps by blocking acid production, thereby reducing gastric acidity.  When Adderall XR<span class="Sup">Â® </span>(20 mg single-dose) was administered concomitantly with the proton pump inhibitor, omeprazole (40 mg once daily for 14 days), the median T<span class="Sub">max</span> of d-amphetamine was decreased by 1.25 hours (from 4 to 2.75 hours), and the median T<span class="Sub">max</span> of l-amphetamine was decreased by 2.5 hours (from 5.5 to 3 hours), compared to Adderall XR<span class="Sup">Â® </span>administered alone.  The AUC and C<span class="Sub">max</span> of each moiety were unaffected.  Therefore, coadministration of Adderall<span class="Sup">Â® </span>and proton pump inhibitors should be monitored for changes in clinical effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f3bda196-af8a-4d0e-b097-afbe94e20bf2"></a><a name="section-6.4.19"></a><p></p>
<h3><span class="Italics">Veratrum Alkaloids</span></h3>
<p class="First">Amphetamines inhibit the hypotensive effect of veratrum alkaloids.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb3a9125-0b76-42b5-8ff1-dbd461a5a057"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_fcfff506-10d8-472f-96db-7d5b0f84d505"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis/Mutagenesis and Impairment of Fertility</h2>
<p class="First">No evidence of carcinogenicity was found in studies in which d,l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<span class="Sup">2</span> body surface area basis.</p>
<p>Amphetamine, in the enantiomer ratio present in Adderall<span class="Sup">Â®</span> (immediate-release)(d- to l- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test <span class="Italics">in vivo</span> and was negative when tested in the E. coli component of the Ames test <span class="Italics">in vitro</span>. d, l-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in <span class="Italics">vitro</span> sister chromatid exchange and chromosomal aberration assays.</p>
<p>Amphetamine, in the enantiomer ratio present in Adderall<span class="Sup">Â®</span> (immediate-release)(d- to l- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<span class="Sup">2</span> body surface area basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_cd22ce67-766e-43d2-b993-559654a3f7f3"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_97ff3c62-6883-4e87-9cfb-2f179e42f0ab"></a><a name="section-6.7.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e59413ba-495e-4e6b-98f2-28a46250d556"></a><a name="section-6.7.1.1"></a><p></p>
<h4><span class="Underline">Pregnancy Category C</span></h4>
<p class="First">Amphetamine, in the enantiomer ratio present in Adderall<span class="Sup">Â®</span> (d- to l- ratio of 3:1), had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and 8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<span class="Sup">2</span> body surface area basis. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times that of a human dose of 30 mg/day [child] on a mg/m<span class="Sup">2</span> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.</p>
<p>A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,l-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.</p>
<p>There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>, tracheo-<span class="product-label-link" type="condition" conceptid="4149721" conceptname="Esophageal fistula">esophageal fistula</span>, and <span class="product-label-link" type="condition" conceptid="4004155" conceptname="Anal atresia">anal atresia</span> (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_bbba875f-059c-452b-84b2-4f339f2fafd1"></a><a name="section-6.7.2"></a><p></p>
<h3><span class="Italics">Nonteratogenic Effects</span></h3>
<p class="First">Infants born to mothers dependent on amphetamines have an increased risk of <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span> and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and significant <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87c5356a-5bf3-49ac-b40a-4f8ca73fd814"></a><a name="section-6.8"></a><p></p>
<h2>Usage in Nursing Mothers</h2>
<p class="First">Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a0d6ed71-2e79-4512-bf62-813aa01727e1"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Long-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age with Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder described under <span class="Bold"><a href="#i4i_indications_id_29a35259-a305-4821-ad39-1a93075c30b4">INDICATIONS AND USAGE</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_665f8295-4d9d-453a-a024-f47cec430a56"></a><a name="section-6.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Adderall<span class="Sup">Â®</span> has not been studied in the geriatric population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_9c08662d-1da7-408f-99fd-8aee26f1f706"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b7ada52-daef-40b2-9e9d-a6a2c5922317"></a><a name="section-7.1"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevation of blood pressure, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. There have been isolated reports of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> associated with chronic amphetamine use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3263705a-d53a-4475-8b61-df28adc9095a"></a><a name="section-7.2"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic episodes</span> at recommended doses, overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="4294887" conceptname="Cluttering">logorrhea</span>, dermatillomania.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2375ebfb-9988-4843-902b-14db865396ce"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ff45fa9-8bba-46f2-9cdf-c0c7f606c5eb"></a><a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Dryness of the mouth, unpleasant taste, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, other <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>. <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> may occur as undesirable effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be0aec75-3d8c-4b52-b867-74aecb375bd8"></a><a name="section-7.5"></a><p></p>
<h2>Allergic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_311801ee-d303-4acd-a099-ea9093fd0e5e"></a><a name="section-7.6"></a><p></p>
<h2>Endocrine</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, changes in libido, frequent or prolonged erections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdeb3ebb-b673-407e-a93c-711d4a9777df"></a><a name="section-7.7"></a><p></p>
<h2>Skin</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2bf7a782-4671-497d-8198-be7597720377"></a><a name="section-7.8"></a><p></p>
<h2>Musculoskeletal </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_aa2c5177-e5f0-41f8-b80f-a98bb9d4233e"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is a Schedule II controlled substance.</p>
<p>Amphetamines have been extensively abused. Tolerance, extreme psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and severe social <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG. Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with amphetamines include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b86f75f4-38fe-4d76-ba70-bc37aaf2f9e2"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_428a7bcf-5729-4bde-a70f-f40e4e2a6cae"></a><a name="section-9.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First">Manifestations of acute overdosage with amphetamines include <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, rapid respiration, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, assaultiveness, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, panic states, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation.</p>
<p>Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. Fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is usually preceded by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1112c87a-e2fc-48dc-88dc-24f5a6b3929b"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Consult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> if <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> is present. If acute, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_07b0085c-1a92-4086-8b7d-c841e667ddaf"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Regardless of indication, amphetamines should be administered at the lowest effective dosage, and dosage should be individually adjusted according to the therapeutic needs and response of the patient. Late evening doses should be avoided because of the resulting <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_445b9505-882c-4440-9a20-814a6cf21ea3"></a><a name="section-10.1"></a><p></p>
<h2>Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder</h2>
<p class="First">Not recommended for children under 3 years of age. In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.</p>
<p>In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.</p>
<p>Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_63dd324b-7fe5-4bff-89de-51fcb329dc89"></a><a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></h2>
<p class="First">Usual dose 5 mg to 60 mg per day in divided doses, depending on the individual patient response.</p>
<p><span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span> seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f239ff2b-e944-408e-82e8-75339771bf43"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Adderall<span class="Sup">Â®</span> (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is supplied as follows:</p>
<p>5 mg: White to off-white, round, flat-faced beveled edge tablet with four partial bisects debossed with 5 on one side and debossed with dp on the other side.  They are available in bottles of 100 tablets (NDC 57844-105-01).</p>
<p>7.5 mg: Blue, oval, biconvex tablet with two partial bisects debossed with 7.5 on one side and one full bisect and two partial bisects debossed with d | p on the other side.  They are available in bottles of 100 tablets (NDC 57844-117-01).</p>
<p>10 mg: Blue, round, biconvex tablet with one full bisect and two partial bisects debossed with 1 | 0 on one side and debossed with dp on the other side. They are available in bottles of 100 tablets (NDC 57844-110-01).</p>
<p>12.5 mg: Peach, round, flat-faced beveled edge tablet debossed with 12.5 on one side and one full bisect and two partial bisects debossed with d | p on the other side. They are available in bottles of 100 tablets (NDC 57844-112-01).</p>
<p>15 mg: Peach, oval, biconvex tablet with two partial bisects debossed with 15 on one side and one full bisect and two partial bisects debossed with d | p on the other side. They are available in bottles of 100 tablets (NDC 57844-115-01).</p>
<p>20 mg: Peach, round, biconvex tablet with one full bisect and two partial bisects debossed with 2 | 0 on one side and debossed with dp on the other side. They are available in bottles of 100 tablets (NDC 57844-120-01).</p>
<p>30 mg: Peach, round, flat-faced beveled edge tablet with one full bisect and 2 partial bisects debossed with 3 | 0 on one side and dp on the other side. They are available in bottles of 100 tablets (NDC 57844-130-01).</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.</p>
<p><span class="Bold">Teva Select Brands</span>, Horsham, PA 19044</p>
<p>Division of Teva Pharmaceuticals USA</p>
<p>Rev. G 4/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_1156097b-0766-462b-9203-0e89121b3ee3"></a><a name="section-12"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Adderall</span><span class="Sup">Â®Â </span>(<span class="Italics">ADD-ur-all</span>)<span class="Bold"> (CII)</span><br>(Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product))<br></p>
<p>Read the Medication Guide that comes with Adderall<span class="Sup">Â®</span> before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your childâ€™s treatment with Adderall<span class="Sup">Â®</span>.</p>
<div class="Warning">
<a name="i4i_table_id_feab5cc6-086b-4568-9f31-688cc8818ad0"></a><a name="section-12.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">What is the most important information I should know about Adderall<span class="Sup">Â®</span>?Â </span></p>
<p><span class="Bold">The following have been reported with use of Adderall<span class="Sup">Â®</span> and other stimulant medicines.Â <br></span></p>
<p><span class="Bold"><span class="Underline">1. Heart-Related Problems:</span></span></p>
<p><span class="Bold">â€¢ <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients who have heart problems or heart defects</span></p>
<p><span class="Bold">â€¢ <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in adults</span></p>
<p><span class="Bold">â€¢ <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and heart rate</span></p>
<p>Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems.</p>
<p>Your doctor should check you or your child carefully for heart problems before starting Adderall<span class="Sup">Â®</span>.</p>
<p>Your doctor should check your or your childâ€™s blood pressure and heart rate regularly during treatment with Adderall<span class="Sup">Â®</span>.</p>
<p><span class="Bold">Call your doctor right away if you or your child have any signs of heart problems such as <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> while taking Adderall</span><span class="Sup">Â®</span><span class="Bold">.</span></p>
<p><span class="Bold"><span class="Underline">2. Mental (Psychiatric) Problems:</span></span></p>
<p><span class="Bold">All Patients</span></p>
<p><span class="Bold">â€¢ new or worse behavior and thought problems</span></p>
<p><span class="Bold">â€¢ new or worse bipolar illness</span></p>
<p><span class="Bold">â€¢ new or worse <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span></span></p>
<p><span class="Bold">Children and Teenagers</span></p>
<dl>
<dt>Â </dt>
<dd>â€¢ new <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms (such as hearing voices, believing things that are not true, are suspicious) or new <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms</dd>
</dl>
<p>Tell your doctor about any mental problems you or your child have, or about a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar illness, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking Adderall</span><span class="Sup">Â®</span><span class="Bold">, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.</span></p>
<p><span class="Bold"><span class="Underline">3. Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaudâ€™s Phenomenon]:</span></span></p>
<dl>
<dt>â€¢</dt>
<dd>Fingers or toes may feel numb, cool, painful</dd>
<dt>â€¢</dt>
<dd>Fingers or toes may change color from <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, to blue, to red</dd>
</dl>
<p>Tell your doctor if you have or your child has <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, skin color change, or sensitivity to temperature in your fingers or toes.</p>
<p><span class="Bold">Call your doctor right away if you have or your child has any signs of unexplained <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> appearing on fingers or toes while taking Adderall<span class="Sup">Â®</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0f659d7c-2994-41dc-8605-1a2fb22b642e"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">What is Adderall<span class="Sup">Â®</span>?</span></p>
<p>Adderall<span class="Sup">Â®</span> is a central nervous system stimulant prescription medicine. <span class="Bold">It is used for the treatment of Attention-Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>). </span>Adderall<span class="Sup">Â®</span> may help increase attention and decrease impulsiveness and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>.</p>
<p>Adderall<span class="Sup">Â®</span> should be used as a part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include counseling or other therapies.</p>
<p>Adderall<span class="Sup">Â®</span> is also used in the treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span> called <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Adderall<span class="Sup">Â®</span> is a federally controlled substance (CII) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep Adderall<span class="Sup">Â®</span> in a safe place to prevent misuse and abuse. Selling or giving away Adderall<span class="Sup">Â®</span> may harm others, and is against the law.</span><span class="Sup">Â Â </span></p>
<p>Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.</p>
</td></tr></tbody>
</table>
<p><span class="Bold">Who should not take Adderall<span class="Sup">Â®</span>?</span></p>
<p><span class="Bold">Adderall</span><span class="Sup">Â®Â </span><span class="Bold">should not be taken if you or your child:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have heart disease or hardening of the arteries</dd>
<dt>â€¢</dt>
<dd>have moderate to severe high blood pressure</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span></dd>
<dt>â€¢</dt>
<dd>have an eye problem called <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></dd>
<dt>â€¢</dt>
<dd>are very anxious, <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span>, or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span></dd>
<dt>â€¢</dt>
<dd>have a history of drug abuse</dd>
<dt>â€¢</dt>
<dd>are taking or have taken within the past 14 days an anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicine called a monoamine oxidase inhibitor or MAOI.</dd>
<dt>â€¢</dt>
<dd>are sensitive to, allergic to, or had a reaction to other stimulant medicines </dd>
</dl>
<p>Adderall<span class="Sup">Â®</span> is not recommended for use in children less than 3 years old.</p>
<p><span class="Bold">Adderall</span><span class="Sup">Â® Â </span><span class="Bold">may not be right for you or your child. Before starting Adderall</span><span class="Sup">Â®Â </span><span class="Bold">tell your or your childâ€™s doctor about all health conditions (or a family history of) including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>heart problems, heart defects, high blood pressure</dd>
<dt>â€¢</dt>
<dd>mental problems including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, bipolar illness, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> or Touretteâ€™s syndrome</dd>
<dt>â€¢</dt>
<dd>liver or kidney problems</dd>
<dt>â€¢</dt>
<dd>circulation problems in fingers and toes</dd>
<dt>â€¢</dt>
<dd>thyroid problems</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or have had an abnormal brain wave test (EEG)</dd>
</dl>
<p>Tell your doctor if you or your child are pregnant, planning to become pregnant, or breastfeeding.</p>
<p><span class="Bold">Can Adderall</span><span class="Sup">Â®Â </span><span class="Bold">be taken with other medicines?</span></p>
<p><span class="Bold">Tell your doctor about all of the medicines that you or your child take including prescription and nonprescription medicines, vitamins, and herbal supplements. </span>Adderall<span class="Sup">Â®</span> and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking Adderall<span class="Sup">Â®</span>.</p>
<p>Your doctor will decide whether Adderall<span class="Sup">Â®</span> can be taken with other medicines.</p>
<p><span class="Bold">Especially tell your doctor if you or your child take:</span></p>
<dl>
<dt>â€¢</dt>
<dd>anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicines including MAOIs</dd>
<dt>â€¢</dt>
<dd>blood pressure medicines</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines</dd>
<dt>â€¢</dt>
<dd>blood thinner medicines</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> medicines that contain decongestants</dd>
<dt>â€¢</dt>
<dd>stomach acid medicines</dd>
</dl>
<p>Know the medicines that you or your child take. Keep a list of your medicines with you to show your doctor and pharmacist.</p>
<p><span class="Bold">Do not start any new medicine while taking Adderall</span><span class="Sup">Â®Â </span><span class="Bold">without talking to your doctor first.</span></p>
<p><span class="Bold">How should Adderall</span><span class="Sup">Â®Â </span><span class="Bold">be taken?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Take Adderall</span><span class="Sup">Â®Â </span><span class="Bold">exactly as prescribed. </span>Your doctor may adjust the dose until it is right for you or your child.</dd>
<dt>â€¢</dt>
<dd>Adderall<span class="Sup">Â®</span> tablets are usually taken two to three times a day. The first dose is usually taken when you first wake in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.</dd>
<dt>â€¢</dt>
<dd>Adderall<span class="Sup">Â®</span> can be taken with or without food.</dd>
<dt>â€¢</dt>
<dd>From time to time, your doctor may stop Adderall<span class="Sup">Â®</span> treatment for a while to check <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms.</dd>
<dt>â€¢</dt>
<dd>Your doctor may do regular checks of the blood, heart, and blood pressure while taking Adderall<span class="Sup">Â®</span>. Children should have their height and weight checked often while taking Adderall<span class="Sup">Â®</span>. Adderall<span class="Sup">Â®</span> treatment may be stopped if a problem is found during these check-ups.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">If you or your child take too much Adderall</span><span class="Sup">Â® </span><span class="Bold">or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away, or get emergency treatment.</span>
</dd>
</dl>
<p><span class="Bold">What are possible side effects of Adderall<span class="Sup">Â®</span>?</span></p>
<p>See â€œ<span class="Bold">What is the most important information I should know about Adderall</span><span class="Sup">Â®</span><span class="Bold">?</span>â€?Â for information on reported heart and mental problems.</p>
<p><span class="Bold">Other serious side effects include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>slowing of growth (height and weight) in children</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, mainly in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>â€¢</dt>
<dd>eyesight changes or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></dd>
</dl>
<p><span class="Bold">Common side effects include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach ache</span> </dd>
<dt>â€¢</dt>
<dd>trouble sleeping</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl>
<p>Adderall<span class="Sup">Â®</span> may affect your or your childâ€™s ability to drive or do other dangerous activities.</p>
<p>Talk to your doctor if you or your child have side effects that are bothersome or do not go away.</p>
<p>This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.</p>
<p><span class="Bold">How should I store Adderall</span><span class="Sup">Â®</span><span class="Bold">?</span><span class="Sup">Â </span></p>
<dl>
<dt>â€¢</dt>
<dd>Store Adderall<span class="Sup">Â®</span> in a safe place at room temperature, 20Â° to 25Â°C (68Â° to 77Â°F). </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Keep Adderall</span><span class="Sup">Â®</span><span class="Bold"> and all medicines out of the reach of children.</span>
</dd>
</dl>
<p><span class="Bold">General information about Adderall</span><span class="Sup">Â®</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Adderall<span class="Sup">Â®</span> for a condition for which it was not prescribed. Do not give Adderall<span class="Sup">Â®</span> to other people, even if they have the same condition. It may harm them and it is against the law. This Medication Guide summarizes the most important information about Adderall<span class="Sup">Â®</span>. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Adderall<span class="Sup">Â®</span> that was written for healthcare professionals. For more information about Adderall<span class="Sup">Â®</span>, please contact Teva Pharmaceuticals at 1-888-838-2872.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">What are the ingredients in Adderall<span class="Sup">Â®</span>?</span></p>
<p><span class="Bold">Active Ingredient: </span>dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate.</p>
<p><span class="Bold">Inactive Ingredients: </span>colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, microcrystalline cellulose and saccharin sodium.  The 5 mg is a white to off-white tablet, which contains no color additives.  The 7.5 mg and 10 mg also contain FD&amp;C Blue #1 Aluminum Lake as a color additive.  The 12.5 mg, 15 mg, 20 mg and 30 mg also contain FD&amp;C Yellow #6 Aluminum Lake as a color additive.</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Teva Select Brands</span>, Horsham, PA 19044</p>
<p>Division of Teva Pharmaceuticals USA</p>
<p>Rev. E 4/2015 </p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ca48c3e1-4414-468d-8369-ec8ab0679970"></a><a name="section-13"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2294"></a><img alt="AdderallÂ® 5 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-01.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23aa676f-95d3-49b4-afdc-d9fb0a9a7801"></a><a name="section-13.1"></a><p></p>
<h2>AdderallÂ® 5 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">105</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span></p>
<p><span class="Bold">5 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_07ca86e1-110c-449d-bb88-1107a0755aba"></a><a name="section-14"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2328"></a><img alt="AdderallÂ® 7.5 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de6d10c5-c7ea-413b-ad08-2650bf059e8e"></a><a name="section-14.1"></a><p></p>
<h2>AdderallÂ® 7.5 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">117</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">7.5 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2ef43287-c791-4b5b-966c-bd8019b0879c"></a><a name="section-15"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2362"></a><img alt="AdderallÂ® 10 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-03.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0710cbc0-ffa9-4317-91aa-ed8615b61055"></a><a name="section-15.1"></a><p></p>
<h2>AdderallÂ® 10 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">110</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">10 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_18dfbfe7-cbea-437b-bbce-4f4bddeb85b5"></a><a name="section-16"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2396"></a><img alt="AdderallÂ® 12.5 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-04.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ae2c8f1-daba-46ff-aedb-f665e67d53c2"></a><a name="section-16.1"></a><p></p>
<h2>AdderallÂ® 12.5 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">112</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">12.5 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_222696c2-394d-4d91-a261-2e6b0557ee42"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2430"></a><img alt="AdderallÂ® 15 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-05.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35507d22-16c1-4bd8-bd17-7515b14f4c7c"></a><a name="section-17.1"></a><p></p>
<h2>AdderallÂ® 15 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">115</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">15 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d53a30b6-f59e-4ff7-9452-fde584f81473"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2464"></a><img alt="AdderallÂ® 20 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-06.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_caad22a7-bb0a-474b-991b-6c5c83fdcaac"></a><a name="section-18.1"></a><p></p>
<h2>AdderallÂ® 20 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">120</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">20 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a27deede-5d11-436b-83f8-ee2025eccb10"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id2498"></a><img alt="AdderallÂ® 30 mg CII 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81&amp;name=image-07.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54a7b442-1692-4e56-9a96-356faf6e8c12"></a><a name="section-19.1"></a><p></p>
<h2>AdderallÂ® 30 mg CII 100s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 57844-<span class="Bold">130</span>-01</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">Adderall<span class="Sup">Â®</span></span><br>(Dextroamphetamine Saccharate,<br>Amphetamine Aspartate,<br>Dextroamphetamine Sulfate and<br>Amphetamine Sulfate Tablets)<br><span class="Italics">(Mixed Salts of a Single Entity</span><br><span class="Italics">Amphetamine Product)</span><br><span class="Bold">30 mg</span></p>
<p>PHARMACIST: DISPENSE THE<br>ACCOMPANYING MEDICATION GUIDE<br>TO EACH PATIENT.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-105</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">1.25Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">1.25Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">1.25Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">1.25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5;dp</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-105-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">11/13/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">11/13/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-117</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">1.875Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">1.875Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">1.875Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">1.875Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7;5;d;p</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-117-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/03/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">03/03/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-110</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">2.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">2.5Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">2.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">2.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1;0;dp</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-110-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">02/03/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">02/03/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-112</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">3.125Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">3.125Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">3.125Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">3.125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">12;5;d;p</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-112-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">06/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">3.75Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">3.75Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">3.75Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">3.75Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">15;d;p</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-115-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">06/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-120</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">5Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2;0;dp</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-120-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">02/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">02/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADDERALLÂ 		
					</strong><br><span class="contentTableReg">dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57844-130</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SACCHARATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SACCHARATE</td>
<td class="formItem">7.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE ASPARTATE MONOHYDRATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE ASPARTATE MONOHYDRATE</td>
<td class="formItem">7.5Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">7.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMPHETAMINE SULFATE</strong> (AMPHETAMINE) </td>
<td class="formItem">AMPHETAMINE SULFATE</td>
<td class="formItem">7.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3;0;dp</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57844-130-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">02/06/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040422</td>
<td class="formItem">02/06/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Teva Select Brands
							(001627975)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b83be27f-26a1-4103-85f0-0132bf6a4f2a</div>
<div>Set id: f22635fe-821d-4cde-aa12-419f8b53db81</div>
<div>Version: 5</div>
<div>Effective Time: 20150804</div>
</div>
</div>Â <div class="DistributorName">Teva Select Brands</div></p>
</body></html>
